[1]
Nyambe, H. et al. 2022. The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment. Nusantara Medical Science Journal. 6, 2 (Jan. 2022), 103–115. DOI:https://doi.org/10.20956/nmsj.v6i2.18857.